The use of systemic corticosteroids in asthma management in Latin American countries

Bibliographic Details
Title: The use of systemic corticosteroids in asthma management in Latin American countries
Authors: Jorge F. Maspero, MD, FCCP, FAAAAI, Alvaro A. Cruz, MD, PhD, Cesar Fireth Pozo Beltran, MD, Abraham Ali Munive, MD, Felicia Montero-Arias, MD, Ramses Hernandez Pliego, MD, Hisham Farouk, BCPS, MScPharm
Source: World Allergy Organization Journal, Vol 16, Iss 4, Pp 100760- (2023)
Publisher Information: Elsevier, 2023.
Publication Year: 2023
Collection: LCC:Immunologic diseases. Allergy
Subject Terms: Systemic corticosteroids, Severe asthma, Latin America, Biological products, Adverse effects, Immunologic diseases. Allergy, RC581-607
More Details: The stepwise treatment approach recommended by the Global Initiative for Asthma (GINA) includes systemic corticosteroids (SCS) suggested as a final step if asthma is severe and/or difficult to treat. Yet, despite the effectiveness of SCS, they are also associated with potentially irreversible adverse outcomes such as type 2 diabetes, adrenal suppression, and cardiovascular disease. Based on recent data indicating that the risk of developing these conditions can increase after as few as 4 short-term (burst) courses of SCS, even patients with mild asthma who receive SCS occasionally for exacerbations are also at risk of these events. As a result, recent updates by GINA and the Latin American Thoracic Society recommend decreasing SCS use by optimizing administration of non-SCS therapies and/or increasing the use of alternatives, such as biologic agents. Recent and ongoing studies characterizing treatment patterns among patients with asthma have revealed alarming trends suggesting the widespread overuse of SCS around the world. In Latin America, asthma prevalence is approximately 17%, and data suggest that the majority of patients have uncontrolled disease. In this review, we summarize currently available data on asthma treatment patterns in Latin America, which indicate that SCS are prescribed to 20–40% of patients with asthma considered to be well controlled and over 50% of patients with uncontrolled disease. We also offer potential strategies to help reduce SCS use for asthma in everyday clinical practice.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1939-4551
Relation: http://www.sciencedirect.com/science/article/pii/S1939455123000200; https://doaj.org/toc/1939-4551
DOI: 10.1016/j.waojou.2023.100760
Access URL: https://doaj.org/article/0af85c17e8af442cb551960143c285e8
Accession Number: edsdoj.0af85c17e8af442cb551960143c285e8
Database: Directory of Open Access Journals
More Details
ISSN:19394551
DOI:10.1016/j.waojou.2023.100760
Published in:World Allergy Organization Journal
Language:English